B
oth AABB and the Foundation for the Accreditation of Cell Therapy (FACT) require assessment and documentation of laboratory proficiency in cell therapy processes. 1 In the United States, TNC, CD34, and cell viability are nongraded PT analytes, but are regulated and must be assessed twice yearly to determine the accuracy and reliability of the reported results.
We have participated in the biannual College of American Pathology's (CAP) stem cell processing (SCP) PT challenges for several years. Each CAP-SCP challenge includes two prepared samples resuspended in commercial tissue culture medium supplemented with 10% human sera. [3] [4] [5] [6] [7] [8] [9] [10] Participants are asked to measure the TNC, CD34 count, and cell viability per institutional procedures. The reported results are analyzed relative to instrumentation, reagents, and CD34 testing platform (single-or dual-stage). Due to the small number of participants and wide variation in testing results, the CAP-SCP PT challenges are currently ungraded.
Another avenue for PT is interlaboratory exchanges. This method is not uncommon for new molecular testing assays or infrequently performed assays. 11 In this respect, allogeneic stem cell products procured through the National Marrow Donor Program (NMDP) can be considered an interlaboratory PT challenge, since these products are tested by both collection and receiving facilities. Unlike commercial PT samples, allogeneic products are fresh and are not subject to dilution or modification by the addition of stabilizing agents or resuspension in tissue culture medium. [3] [4] [5] [6] [7] [8] [9] [10] [12] [13] [14] [15] [16] [17] [18] To assess the utility of allogeneic products for PT, we compared the TNC and CD34 count from 141 peripheral blood hematopoietic progenitor cell apheresis (HPC-A) units received at our institution from external collection facilities over a 3-year period.
MATERIALS AND METHODS

Study design
The study was a 3-year retrospective review of all unrelated allogeneic HPC-A units received by the University of Michigan between January 2011 and December 2013. External and internal testing results for the calculated absolute TNC and CD34 count were compared and analyzed as an interlaboratory PT challenge. Data from the external donor facility included the absolute TNC (310 9 ) and CD34 count (310 6 ) of each unit, product volume (mL), whether it was collected by a NMDP or non-NMDP donor facility, NMDP donor center identification number, donor center location (country, state), donor sex, and age. Donor centers were classified as international, if located outside the United States, or domestic, if located within the continental United States. For domestic donor facilities, the time zone (Eastern, Central, Mountain, Pacific) was also included for analysis. Available internal laboratory data included the absolute TNC and CD34 count, cell viability, percent mononuclear cells (MNCs), hematocrit (Hct; %), platelet (PLT) count (310 9 /L), and transplant cell dose.
Internal cell analysis
Allogeneic products were tested for TNC, CD34 count, cell viability, and sterility testing upon receipt. TNC and complete blood count were performed using an automated cell counter (Sysmex XE-5000, Kobe). The white blood cell (WBC) differential was determined by manual methods. Per protocol, samples with an initial WBC count of more than 3 3 10 11 /L were diluted 1:5 in commercial cell diluent (Cell Pack DCL, Sysmex) and reanalyzed.
For CD34 analysis, a 0.5-mL aliquot was incubated with a cocktail-containing antibodies against CD34, CD45, CD14, and 7-aminoactinomycin D (7-AAD) for 10 minutes, followed by red blood cell lysis and immediate analysis: Samples were not subjected to a wash step or fixation before flow cytometry. CD34 analysis was performed using a dual-stage, four-color modified International Society for Hematotherapy and Graft Engineering (ISHAGE) protocol on a Gallios multichannel flow cytometer (Beckman Coulter). Per ISHAGE, CD34 cells were identified through sequential gating using CD45, CD34, and forward and side scatter (SS) to identify CD341, CD45 
Statistical analysis
The TNC and CD34 count for individual units as measured by the donor center (external) and our institution (internal) were compared by paired t test ( Fig. 1 ) and linear regression. In addition, the absolute difference between donor center and internal cell counts (external countinternal count) and the percent (%) difference (external count -internal count/external count) were also calculated. Results were reported as the mean 6 standard deviation (SD). The 95% limits of agreeability (95% LA) were calculated and plotted as described. 23, 24 Specifically, the percent difference was plotted against the mean absolute CD34 count ([external count 1 internal count] 4 2).
Results falling between the mean 6 1.96SD were considered within the 95% LA. Differences between international and domestic HPC-A products were compared by standard t test. Linear regression, graphing, and t tests were performed using computer software (Kaleidograph, Synergy Software). Categorical variables were compared by chi square using computer software (Epi Info, Centers for Disease Control and Prevention).
CAP-SCP PT analysis
CAP-SCP PT samples (2.5-mL sample) were shipped overnight with cold gel packs. Upon arrival, samples were mixed and sterilely split into four 0.5-mL aliquots in a biologic hood for hematology, flow cytometry, Gram stain, and bacterial culture. With one exception, all samples were tested and analyzed on the day of receipt per institutional protocols as described. All samples were tested within 24 hours of receipt per CAP requirements. TNC and WBC count were performed on a cell counter (XE-5000, Sysmex). CD34 analysis was performed using a modified ISHAGE protocol as described and reported as %CD34 and CD34 count (310 6 ). In addition, the list mode data (LMD) files were reanalyzed at a later date by a second individual, who was blinded with regard to the original testing results. The %CD34 was determined without 7-AAD gating as recommended by the United Kingdom National External Quality Assessment program (UK NEQA). 17 For analysis, our internal institutional CAP-SCP results for TNC and CD34 results were plotted against the manufacturer's certificate of analysis (CoA) as provided by CAP. [3] [4] [5] [6] [7] [8] [9] [10] To compare our results with other participants, the mean 6 1SD and 6 2SD for all peer institutions were plotted in parallel. For CD34, our results were compared only to participants using a dual-stage platform for CD34 enumeration. As a control, we performed the same analysis for the %CD3 and absolute CD3 count ( 310 6 ) results, which were also included in the CAP-SCP challenges. Internal results were compared to CoA and participant mean by paired t test. In addition, the absolute and percent difference in TNC, CD34, and CD3 results were calculated and compared.
RESULTS
External allogeneic HPC-A units
A total of 141 units HPC-A units for 131 patients were received from 40 external collection centers between 2011 and 2013 ( Table 1 ). The vast majority of units (130, 92%) were collected at NMDP-affiliated centers. Sixty-nine units were from international collection centers and 72 units were from domestic centers located in the United States. Domestic units were collected from 23 NMDP centers located in 15 states. Half of all domestic units (39/72, 54%) were collected at centers located in the same time zone (Eastern) as our facility.
Most international units were from European donor centers. Germany was the largest international supplier of HPC-A units (55, 83%), with nearly 75% of all international units (49/66) coming from a single collection center. A limited number of units (1-2 units) were received from eight other countries including Poland (2), Denmark (1), England (3), Portugal (2), Sweden (2), Netherlands (1), Israel (2), and Australia (1). All non-NMDP units were from European collection centers. HPC-A units from domestic and international centers were comparable with few differences relative to donor characteristics, volume, total cell counts, and cell dose ( Table 2) .
Comparison of TNC
External and internal TNC were available in 128 units ( Fig. 1 ). Paired counts were initially compared by linear regression ( Fig. 2A ), which showed a strong correlation (R 5 0.93) with a slope (m) of nearly 1 (m 5 0.86). The same tight correlation was observed for both international (R 5 0.92) and domestic units (R 5 0.93). The y-intercept (17.3) indicated a trend toward higher internal TNC, especially for domestic units. The absolute and percent difference in TNC were also determined and compared (Figs. 2B and 2C). Overall, the TNC in 84% (108/128) of units were within 610% of each other (Fig. 2C ). For domestic units, there was a slight bias toward higher internal counts (64% of units), although the median percent difference was modest (23.3%, Table 3 ). There was a trend (p 5 0.07) toward higher internal TNC for HPC-A units collected by centers located in the Eastern time zone.
External counts for international units were, in general, remarkably close to internal counts ( Table 3 ). The mean and median percent differences were 1.35 and 5.1%, respectively. We also examined TNC by continent and donor center since 75% of all international units came from a single donor center (107). As shown in Table 3 , external TNC from donor center 107 tended to be 5% higher than internal counts (p 5 0.002).
Comparison of CD34 counts
Paired external and internal CD34 counts were available in 122 (86.5%) units (Fig. 1 ). Like TNC, there was a close correlation between external and internal CD34 counts (Fig. 3A) . As shown in Table 3 , there was no significant difference in mean CD34 counts between external donor facilities and internal testing (p 5 0.73), with a median percent difference of 21% (95% LA, 250%, 147%; Fig.  3C ). Units that exceeded 95% LA tended to have lower CD34 counts. Overall, the internal CD34 count was within 610% of the collecting facility's yield in 72 units (59%) and within 20% in 94 units (77%).
When examined by donor center location, 41 of 55 (74.5%) domestic units were within 610%, with a slight bias toward higher internal CD34 counts at our facility (median % difference, 20.8%; 95% LA, 244.7, 43.1). The median percent difference in CD34 counts for international units was 20.7% (Table 3 ; 95% LA, 245.5, 44.1), with nearly half falling within 610%.
TNC and CD34 results by year
We also compared TNC and CD34 counts by calendar year (Fig. 4) . There was a small improvement in TNC correlation ( Table 3 ). There was also no significant difference in the relative distribution of international (43%-52%) versus domestic HPC-A units over the 3-year period.
There was a good correlation between CD34 counts over time ( Fig. 4B ; R 5 0.88-0.90). A comparison of counts by paired t test showed no significant differences although there was a trend toward higher external counts in 2013 (p 5 0.07; Table 1 , 4.6%). The higher external counts may reflect a 10% increase in the number of domestic HPC-A units collected by centers located within the Eastern time zone (36% in 2013).
Outlier analysis
A detailed analysis was performed in 10 cases in which the percent difference in either TNC or CD34 count was more than 50% (Table S1 [available as supporting information in the online version of this paper], bold). Outlier counts were observed with both international (n 5 5) and domestic (n 5 5) units. A majority of units (6/10) were collected during the 2011 calendar year (6/33, 18%) versus three (6%) in 2012 and only one (2%) in 2013. All six cases in 2011 demonstrated either higher internal TNC (70%-382%) or higher CD34 counts (63%-94%). Four samples showed decreases in both TNC and CD34 count, as well as lower cell viability (88%-94%) suggesting some product deterioration during transit.
Commercial PT performance
We participate in a commercial stem cell proficiency challenge offered biannually by CAP. We compared our results for TNC, CD34, and CD3 from 16 PT samples against the expected results based on the manufacturer's CoA and the mean result (61SD and 62SD) for peer participants.
In general, our results for TNC fell within 62SD for all challenges (Fig. 5A) . In paired t tests, our results were 21.8% lower than the CoA (p 5 0.027; range, 223.4% to 115.3%) but 4.9% higher than the participant mean (p 5 0.07; range, 29%, 6.8%). The mean coefficient of variation (CV) across all TNC challenges was 9.2% 6 2.3%. There was no CoA for %CD34, limiting our analysis to peer participants. As shown in Fig. 5B , internal results for %CD34 were within 61SD for dual-stage users (p 5 0.48; CV range, 9.3%-46.9%). In contrast, the absolute CD34 count (310 6 ) was consistently low (22SD, Fig. 5C ) relative to the CoA (P 5 0.007) and participant mean (p 5 0.002; CV range, 14%-59.4%). Based on the recommendations of the UK NEQA program for HPC analysis, we reanalyzed the LMD file from each challenge keeping the 7-AAD gate open. 17 There was no significant change in CD34 results (data not shown). We also examined whether there was sufficient sample to collect the minimum number of cell events as recommended by ISHAGE (>75 3 10 3 CD451
cells, >100 CD451, CD341 cells). 19 Although sufficient CD451 events were collected, the minimum number of CD341 events could not be reached in three samples (range, 41-67 CD34 cells).
Because of our consistently low absolute CD34 counts, we also examined our performance with %CD3 and absolute CD3 (310 6 ) counts during the same challenges. Unlike CD341 cells, CD31 cells are plentiful and account for 55% to 84% of all peripheral blood lymphocytes. 25 As shown in Figs. 5D and 5E, the %CD3 (p 5 0.0005) and absolute CD3 counts (p 5 0.0001) were significantly lower than the participant mean. The lower TNC, %CD3, and absolute CD3 counts suggest some sample deterioration before receipt and testing.
DISCUSSION
The TNC and viable CD34 count are critical to clinical decision making during stem cell collection and transplantation. Numerous clinical studies over two decades *Limited to HPC-A products with both external and internal testing results (see Fig. 1 ). †Absolute counts from external donor facility, reported as mean 6 SD. ‡Internal absolute counts, reported as mean 6 SD. §Paired t test. jjMean (median) difference in absolute counts between external donor center and internal results, where external -internal count. ¶Mean (median) percent (%) difference in absolute counts between external donor center and internal results, where ([external -internal count] 4 2). **Percent difference was 28.9% and 18.9% (n 5 2).
have confirmed the importance of sufficient CD34 cells to ensure adequate long-term engraftment. 22, [26] [27] [28] In marrow transplantation, TNC is often used as an intraoperative surrogate assessment of harvest efficacy, while both TNC and CD34 cell dose are correlated with transplant outcomes. 26, 27 Likewise, both TNC and CD34 count are important for determining the quality of umbilical cord blood for cryopreservation and transplantation. 28 In donors undergoing peripheral blood stem cell collection, the number of circulating CD34 cells determine the timing of collection and the number of procedures required. 29 As a result, TNC, CD34 and cell viability are considered critical analytes subject to PT. 1, 2 In general, PT for TNC and WBC counts is relatively easy given the reproducibility and precision of current automated cell analyzers. 30, 31 In contrast, CD34 PT has proved particularly challenging due to the complexity of testing and a host of preanalytical and technical factors that can separately, and synergistically, influence test results. [12] [13] [14] [15] [16] [17] [18] [19] 32 Moreover, CD34 enumeration is a rare event analysis, which presents additional difficulties for QC, precision, and accuracy. 33 Over the past 20 years, cell therapy PT challenges have been instrumental in identifying many technical and reagent factors that can impact CD34 testing and serve as the basis for today's current best practices. These include the use of Class II and Class III anti-CD34 monoclonal antibody, preferably as CD34-PE conjugate, a multiparameter sequential gating strategy, the importance of acquiring sufficient data events, and inclusion of viability staining. 13, 14, 16, 17, 19 Single-platform testing, which requires the addition of fluorescent beads to samples, is also reported to increase accuracy since it allows a direct internal measure of the number of CD34 cells per volume tested. 12, 13, 17, 33 Dual-platform testing is felt to be less accurate although studies have reported equivalent results when ISHAGE gating is used. 14, 34 Preanalytical variables also influence CD34 PT performance and may account for 40% of the variation observed between participants. 20 One important preanalytical factor is the type of sample: PT samples prepared from HPC-A, which are enriched for CD34 cells, tend to have closer agreement than peripheral blood samples. 20, 34 Marrow is also prone to high variability due to heterogeneity in CD34 staining and cell granularity. 34 Samples for CD34 PT have included stabilized, commercial CD341 tissue culture line (KG1) 35 ; stabilized CD341 acute myeloid leukemia cells 13 ; heparinized whole blood 20 ; blood diluted with donor plasma 32 ; peripheral blood containing a cell preservative [12] [13] [14] [15] [16] ; fresh HPC-A or marrow diluted in phosphatebuffered saline 20 or tissue-culture media (RPMI, X-VIVO) [3] [4] [5] [6] [7] [8] [9] [10] 18 ; and thawed, cryopreserved HPC-A resuspended in tissue culture media (RPMI, Dulbecco's). 16, 18 Other preanalytical factors are the homogeneity of the samples during central processing and aliquoting, sample stability and reproducibility during storage and transport, and sample processing upon receipt. 36 Long delays or improper storage during transport can impact cell content between participating centers, 18 particularly if cells were in the early stages of apoptosis. Studies have shown that 7-AAD, which only measures membrane integrity, is unable to detect cells in early apoptosis and/or poor proliferative capacity. 16, 37, 38 To improve sample stability, some manufacturers add or collect blood in a stabilizing agent. [12] [13] [14] [15] [16] [17] In the United States, CAP-SCP PT samples are prepared from either peripheral blood or HPC-A, resuspended in heparinized X-VIVO 10, a serumfree hematopoietic cell medium marketed for CD34 and lymphocyte cell cultures that is supplemented with 10% autologous serum. 39 Finally, laboratory differences in sample processing (cell lysis reagent, wash/no wash) can introduce additional sample variation before analysis. 14, 20, 40 Our data suggest that allogeneic HPC-A products can also serve as a PT challenge, with many advantages over commercial PT samples. HPC-A samples are large volume and significantly less subject to aliquot and sampling error. In addition, HPC-A are not subject to additives that may alter cell characteristics. Moreover, HPC-A products are packaged and transported using an established validated method to ensure cell viability and stability.
Allogeneic HPC-A are still subject to interlaboratory variability due to sample processing and technical factors including testing platform, instrumentation and software, staining reagents, pipetting, gating strategy, number of acquired events, and operator experience. [12] [13] [14] [15] [16] [17] [18] 20 Nonetheless, we observed a satisfactory performance between our results and the majority of external sites. Overall, the median percent difference for TNC (20.15%) and CD34 (21.1%) count was very low, with 85% TNC and 59% CD34 count falling within 610% of the external facility. These results compare favorably to the UK NEQA PT program, in which participants are expected to fall within the median 50% (25th-75th percentile) 6 15% over three successive challenges. 14, 17 Our experience using allogeneic HPC-A products as a paired PT challenge was significantly better than CAP-SCP PT challenges. TNC using the cell counter (XE-5000, Sysmex) was slightly lower than the CoA but still within 62SD. Likewise, the results for %CD34 fell within 61SD for institutions using dual-platform testing. In contrast, we consistently had absolute CD34 values that fell near or below 2SD, even after reanalysis without 7-AAD gating per UK NEQA guidelines. 17 A comparison of %CD3 and absolute CD3 counts during the same challenges also showed significantly lower %CD3 and absolute CD3 counts. Altogether, we believe that the lower mean TNC, %CD3, and absolute CD3 suggest some sample degradation. Stability studies with the cell counter (XE-5000, Sysmex) have shown a 4% decrease in lymphocyte count within 24 hours at cool temperatures. 41 Probable sample degradation was also evident during flow cytometric analysis in many samples. Sample degradation would also contribute to our inability to reach the minimum number of CD34 events in 18% of samples. 19 In addition to preanalytical factors, there were three technical differences that could also contribute to the variability we observed with commercial PT samples. One is our use of a newer multichannel (10-color) flow cytometer, which was an outlier among CAP participants. Both flow cytometry instrumentation and analytical software are variables effecting CD34 PT and lymphocyte subtyping. 14, 42 Furthermore, we use a modified ISHAGE protocol that includes CD14-FITC and a different CD45 fluorochrome (electron-coupled dye). The inclusion of CD14 for gating is recommended in the SIHON protocol developed in the Netherlands. 14, [20] [21] [22] Gating for CD341 CD14-cells excludes nonspecific CD34 binding by Fcc receptors on monocytic cells, which are up regulated by G-CSF and GM-CSF, as well as CD341 CD141 early monocytes present in marrow and peripheral blood (5%-10%). [20] [21] [22] 34 It is reported that the addition of CD14 in cord cell analysis can decrease the %CD34 cells by 0.9% to 47%. 21 Similarly,
Brecher and coworkers 18 reported that institutions using CD14 had a lower %CD34 in 40% to 80% of PT samples. In contrast, Levering and coworkers 14 found no significant difference in CD34 results between ISHAGE and SIHON gating strategies after reviewing the results of 64 PT samples. Likewise, our %CD34 was very close to the mean for dual-platform users in CAP-SCP challenges (Fig. 5B) . Finally, we observed a very good concordance in CD34 enumeration between our center and other facilities, with a slight positive bias toward higher internal CD34 counts (median, 1%) using our modified ISHAGE protocol. Some of the earliest CD34 PT challenges were plagued by wide interlaboratory variability, especially with fresh samples. 18, 20, 32, 35 Chang and Ma, 32 reporting on an Australasian PT challenge using samples diluted in human plasma, showed that 65% of centers were outside the recommended range (610% median). In an early PT challenge involving 21 samples and 10 participating centers in North America, the CV for %CD34 ranged from 3.7% to 159%. 18 Even when participants were provided both reagents and a standard gating protocol, CVs for %CD34 ranged from 34% to 106% due to nontechnical factors. 20 A survey of current CAP-SCP challenges shows similar variability: The CV for absolute CD34 count ranges from 14% to 59.4% for dual platform and 11% to 54.5% for single platform.
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Better results are reported using stabilized and/or preserved samples, often coupled with central review of LMD files and gating strategies for poor performing laboratories. 13, 14, 16, 17 The former New York State Department of Health CD34 PT program, which used short-term stabilized cell samples, was able to progressively improve PT challenge performance. 16 Likewise, the UK NEQA program prepares and distributes preserved samples that stably retain CD34 cell expression for up to a year. 12, 13, 17 As a result, the UK NEQA program has decreased variability to CV of less than 10%. 13, 17 The Netherlands has also converted to the use of long-term stabilized samples for their CD34 PT program with a significant decrease in variability. 14 The use of stabilized PT samples, however, does have some caveats. 17 The stabilizer impacts cell permeability, affecting both SS and 7-AAD staining. As a consequence, participants are advised to exclude 7-AAD from gating and extend the SS gate. 17 Conversely, the ability of preservation to manufacture 7-AAD1, CD341, CD451 cells can be exploited for QC. Gutensohn and colleagues validated the use of commercial, preserved CD341 cells as an internal positive control for routine CD34 analysis.
In summary, we have demonstrated that allogeneic HPC-A products can serve as an external PT challenge for TNC and CD34 enumeration. HPC-A products may be a more accurate assessment of laboratory proficiency than some commercial PT samples, which are subject to preanalytic variation due to sample preparation techniques, sample homogeneity, and sample stability. 33 
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